Dongkuk Pharmaceutical has announced a name change to 'DK Centellian' as it seeks to expand its business into the health and beauty sectors.
On October 12, the company held a board meeting where it resolved to pursue the name change to target the global market.
The company plans to broaden its focus from its existing domestic pharmaceutical business to include treatment and prevention, as well as health and beauty. The new name reflects its vision of 'Science based health and beauty.'
To facilitate the name change, Dongkuk Pharmaceutical will present an amendment to its articles of incorporation at an extraordinary shareholders' meeting scheduled for November 27.
A company representative stated, "We are pursuing the name change to engage with global customers in a broader business area that encompasses health and beauty, beyond just prevention and treatment."
Meanwhile, Dongkuk Pharmaceutical is expected to join the '1 trillion won club' this year, buoyed by strong performance in its healthcare business. Last year, eight pharmaceutical companies, including Yuhan Corporation, GC Green Cross, Chong Kun Dang, Kwangdong Pharmaceutical, Daewoong Pharmaceutical, Hanmi Pharmaceutical, HK inno.N, and Boryung, surpassed 1 trillion won in annual revenue.
According to the Financial Supervisory Service's electronic disclosure system, Dongkuk Pharmaceutical reported sales of 509.9 billion won and an operating profit of 53.4 billion won in the first half of this year, marking increases of 11.5% and 12.6%, respectively, compared to the previous year. Notably, sales from its healthcare business, including cosmetics, reached 202.9 billion won, a 28.7% increase from 157.7 billion won in the same period last year, driving overall performance growth.
On October 12, the company held a board meeting where it resolved to pursue the name change to target the global market.
The company plans to broaden its focus from its existing domestic pharmaceutical business to include treatment and prevention, as well as health and beauty. The new name reflects its vision of 'Science based health and beauty.'
To facilitate the name change, Dongkuk Pharmaceutical will present an amendment to its articles of incorporation at an extraordinary shareholders' meeting scheduled for November 27.
A company representative stated, "We are pursuing the name change to engage with global customers in a broader business area that encompasses health and beauty, beyond just prevention and treatment."
Meanwhile, Dongkuk Pharmaceutical is expected to join the '1 trillion won club' this year, buoyed by strong performance in its healthcare business. Last year, eight pharmaceutical companies, including Yuhan Corporation, GC Green Cross, Chong Kun Dang, Kwangdong Pharmaceutical, Daewoong Pharmaceutical, Hanmi Pharmaceutical, HK inno.N, and Boryung, surpassed 1 trillion won in annual revenue.
According to the Financial Supervisory Service's electronic disclosure system, Dongkuk Pharmaceutical reported sales of 509.9 billion won and an operating profit of 53.4 billion won in the first half of this year, marking increases of 11.5% and 12.6%, respectively, compared to the previous year. Notably, sales from its healthcare business, including cosmetics, reached 202.9 billion won, a 28.7% increase from 157.7 billion won in the same period last year, driving overall performance growth.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.